Clinical Trials Logo

Clinical Trial Summary

This randomized clinical trial will evaluate the benefit of platelet-rich plasma (PRP) in the treatment of qualitative olfactory dysfunction (parosmia). PRP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. The investigators have completed a randomized controlled trial here, ending in 2022, evaluating it's use in post-SARS-CoV-2 olfactory loss which demonstrated safety and efficacy. Therefore, the investigators aim to assess the ability of PRP to improve olfactory function in patients with parosmia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06283745
Study type Interventional
Source Stanford University
Contact Homer Abaya, BS
Phone (650) 725-6500
Email habaya@stanford.edu
Status Not yet recruiting
Phase N/A
Start date March 23, 2024
Completion date March 22, 2027